Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of Vargatef in advanced non-small cell lung cancer
2014-005016-42Phase 2Completed
- Sponsor
- University of Turin, Department of Oncology
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by University of Turin, Department of Oncology. Primary endpoint: Progression-free survival. Started Mar 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005016-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005016-42.